Article

Selection-free, high frequency genome editing by homologous recombination of human pluripotent stem cells using Cas9 RNP and AAV6

2018-01-23

Abstract excerpt

Combination of genome editing and human pluripotent stem cells (hPSCs) offers a platform for in vitro disease modeling, drug discovery and personalized stem cell therapeutics. However, incorporation of large modifications using CRISPR/Cas9-based genome editing in hPSCs typically requires the use of selection markers due to low editing efficiencies. Here we report a novel editing technology in hPSCs using Cas9 pro...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 63f15890-9f43-5c54-9b74-bec141230b88
DOI: 10.1101/252163

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Selection-free, high frequency genome editing by homologous recombination of human pluripotent stem cells using Cas9 RNP and AAV6DOI 10.1101/252163Read

Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells.Semantic proximity Read

CRISPR/Cas9 genome editing in human hematopoietic stem cells.Semantic proximity Read

Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6Semantic proximity Read

A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells.Semantic proximity Read

Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell diseaseSemantic proximity Read

Clinical genome editing to treat sickle cell disease—A brief updateSemantic proximity Read

Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34 <sup>+</sup> cell therapy to induce fetal hemoglobin for sickle cell diseaseSemantic proximity Read

A Universal Approach to Target Various HBB Gene Mutations in Hematopoietic Stem/Progenitor Cells for Beta-Thalassemia Gene Therapy by CRISPR/Cas9 and the rAAV6 VectorSemantic proximity Read

Genome editing strategies for targeted correction of β-globin mutation in sickle cell disease: From bench to bedside.Semantic proximity Read

Efficient Correction of the Sickle Mutation in Human Hematopoietic Stem Cells Using a Cas9 Ribonucleoprotein ComplexSemantic proximity Read

Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34+ cell therapy to induce fetal hemoglobin for sickle cell diseaseSemantic proximity Read

CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells.Semantic proximity Read